GuruGary confessed to never having seen a public company's CEO build and own private CDMO's in all his years as a biotech investor. What about you, Doc?
Advent received development grants from the U.K. based on its independence from NWBO
Doc logic,
IMO, Northwest Biotherapeutics got the funding from the Cambridgeshire and Peterborough Development Authority.
Phase 1a cost approximately £3.5 million ($4.6 million), including the double shift costs, and covered the support facilities for the first two manufacturing suites, which had already been built. Approximately £1.35 million ($1.77 million) of the Phase 1a cost was funded through a competitive loan from the Cambridgeshire and Peterborough Development Authority. This funding was instrumental in enabling the Sawston facility to reach initial manufacturing readiness. The Company is very grateful to the Development Authority for this funding, and is looking forward to continuing to work with the Authority.
“Advent received development grants from the U.K. based on its independence from NWBO. “
Mendacious. No proof of that. The only advantage I have seen was when revenue goals were not to be met by the development agreement NWBO could give a contract to Advent to claim revenue.